The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal

BACKGROUND: Oral semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog that has been associated with improvements in glycated hemoglobin (HbA1c) and body weight versus sodium-glucose cotransporter-2 inhibitor empagliflozin and injectable GLP-1 receptor agonist dulaglutide in the PIONEER 2 cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkin, Samuel J. P., Carvalho, Davide, Costa, Catarina, Conde, Vasco, Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845275/
https://www.ncbi.nlm.nih.gov/pubmed/35164855
http://dx.doi.org/10.1186/s13098-022-00801-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845275/
https://www.ncbi.nlm.nih.gov/pubmed/35164855
http://dx.doi.org/10.1186/s13098-022-00801-4

Ejemplares similares